Literature DB >> 26365559

Treatment of vitamin D deficiency in cystic fibrosis.

Supavit Chesdachai1, Vin Tangpricha2.   

Abstract

Vitamin D deficiency occurs frequently in patients with cystic fibrosis (CF). Vitamin D is important for optimal mineralization of bone and may be important for other comorbidities commonly occurring in patients with CF. Vitamin D deficiency in patients with CF can arise from various causes including pancreatic exocrine insufficiency, lack of outdoor activity, and alterations of vitamin D metabolism. Due to fat malabsorption stemming from pancreatic insufficiency, higher oral doses of vitamin D are necessary to correct and maintain optimal vitamin D status in patients with CF. Recent studies have demonstrated that higher vitamin D status is associated with better lung function and that vitamin D therapy may help recovery from pulmonary exacerbations of CF. The mechanisms by which vitamin D may exert its beneficial actions in CF are unclear but likely related to the role vitamin D has in modulating the adaptive and innate immune response. Large randomized clinical studies to evaluate the potential role of vitamin D as adjunctive therapy in CF that goes beyond bone are necessary. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26365559      PMCID: PMC4786457          DOI: 10.1016/j.jsbmb.2015.09.013

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  36 in total

1.  Failure of high-dose ergocalciferol to correct vitamin D deficiency in adults with cystic fibrosis.

Authors:  Michael P Boyle; Michelle L Noschese; Sharon L Watts; Marsha E Davis; Shane E Stenner; Noah Lechtzin
Journal:  Am J Respir Crit Care Med       Date:  2005-04-28       Impact factor: 21.405

2.  Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response.

Authors:  Philip T Liu; Steffen Stenger; Huiying Li; Linda Wenzel; Belinda H Tan; Stephan R Krutzik; Maria Teresa Ochoa; Jürgen Schauber; Kent Wu; Christoph Meinken; Diane L Kamen; Manfred Wagner; Robert Bals; Andreas Steinmeyer; Ulrich Zügel; Richard L Gallo; David Eisenberg; Martin Hewison; Bruce W Hollis; John S Adams; Barry R Bloom; Robert L Modlin
Journal:  Science       Date:  2006-02-23       Impact factor: 47.728

3.  Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol, and UV light.

Authors:  Natasha B Khazai; Suzanne E Judd; Leo Jeng; Linda L Wolfenden; Arlene Stecenko; Thomas R Ziegler; Vin Tangpricha
Journal:  J Clin Endocrinol Metab       Date:  2009-03-31       Impact factor: 5.958

4.  Diminished and erratic absorption of ergocalciferol in adult cystic fibrosis patients.

Authors:  R K Lark; G E Lester; D A Ontjes; A D Blackwood; B W Hollis; M M Hensler; R M Aris
Journal:  Am J Clin Nutr       Date:  2001-03       Impact factor: 7.045

Review 5.  Cystic fibrosis genetics: from molecular understanding to clinical application.

Authors:  Garry R Cutting
Journal:  Nat Rev Genet       Date:  2014-11-18       Impact factor: 53.242

6.  An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation.

Authors:  V Tangpricha; A Kelly; A Stephenson; K Maguiness; J Enders; K A Robinson; B C Marshall; D Borowitz
Journal:  J Clin Endocrinol Metab       Date:  2012-03-07       Impact factor: 5.958

7.  Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease.

Authors:  D S Donovan; A Papadopoulos; R B Staron; V Addesso; L Schulman; C McGregor; F Cosman; R L Lindsay; E Shane
Journal:  Am J Respir Crit Care Med       Date:  1998-06       Impact factor: 21.405

8.  Vitamin d deficiency in cystic fibrosis.

Authors:  William B Hall; Amy A Sparks; Robert M Aris
Journal:  Int J Endocrinol       Date:  2010-01-28       Impact factor: 3.257

9.  Cholecalciferol significantly increases 25-hydroxyvitamin D concentrations in adults with cystic fibrosis.

Authors:  Anne Stephenson; Michelle Brotherwood; Ronalee Robert; Eshetu Atenafu; Mary Corey; Elizabeth Tullis
Journal:  Am J Clin Nutr       Date:  2007-05       Impact factor: 7.045

Review 10.  Vitamin D: Update 2013: From rickets prophylaxis to general preventive healthcare.

Authors:  Uwe Gröber; Jörg Spitz; Jörg Reichrath; Klaus Kisters; Michael F Holick
Journal:  Dermatoendocrinol       Date:  2013-11-05
View more
  22 in total

1.  Plasma metabolomics in adults with cystic fibrosis during a pulmonary exacerbation: A pilot randomized study of high-dose vitamin D3 administration.

Authors:  Jessica A Alvarez; Elizabeth Y Chong; Douglas I Walker; Joshua D Chandler; Ellen S Michalski; Ruth E Grossmann; Karan Uppal; Shuzhao Li; Jennifer K Frediani; Rabindra Tirouvanziam; ViLinh T Tran; Vin Tangpricha; Dean P Jones; Thomas R Ziegler
Journal:  Metabolism       Date:  2017-02-11       Impact factor: 8.694

2.  Vitamin D treatment modulates immune activation in cystic fibrosis.

Authors:  T Pincikova; D Paquin-Proulx; J K Sandberg; M Flodström-Tullberg; L Hjelte
Journal:  Clin Exp Immunol       Date:  2017-05-24       Impact factor: 4.330

Review 3.  Role of vitamin D on gut microbiota in cystic fibrosis.

Authors:  Mansi Kanhere; Benoit Chassaing; Andrew T Gewirtz; Vin Tangpricha
Journal:  J Steroid Biochem Mol Biol       Date:  2016-11-03       Impact factor: 4.292

4.  Prospective, Randomized, Double-Blind, Parallel-Group, Comparative Effectiveness Clinical Trial Comparing a Powder Vehicle Compound of Vitamin D With an Oil Vehicle Compound in Adults With Cystic Fibrosis.

Authors:  Wendy A Hermes; Jessica A Alvarez; Moon J Lee; Supavit Chesdachai; Daud Lodin; Ron Horst; Vin Tangpricha
Journal:  JPEN J Parenter Enteral Nutr       Date:  2016-02-22       Impact factor: 4.016

5.  Bolus Weekly Vitamin D3 Supplementation Impacts Gut and Airway Microbiota in Adults With Cystic Fibrosis: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial.

Authors:  Mansi Kanhere; Jiabei He; Benoit Chassaing; Thomas R Ziegler; Jessica A Alvarez; Elizabeth A Ivie; Li Hao; John Hanfelt; Andrew T Gewirtz; Vin Tangpricha
Journal:  J Clin Endocrinol Metab       Date:  2018-02-01       Impact factor: 5.958

6.  Induction of CFTR gene expression by 1,25(OH)2 vitamin D3, 25OH vitamin D3, and vitamin D3 in cultured human airway epithelial cells and in mouse airways.

Authors:  Kristina M DiFranco; Jennifer K Mulligan; Aman S Sumal; Gill Diamond
Journal:  J Steroid Biochem Mol Biol       Date:  2017-01-24       Impact factor: 4.292

7.  Vitamin D for the Immune System in Cystic Fibrosis (DISC): a double-blind, multicenter, randomized, placebo-controlled clinical trial.

Authors:  Vin Tangpricha; Joshua Lukemire; Yuqing Chen; José Nilo G Binongo; Suzanne E Judd; Ellen S Michalski; Moon J Lee; Seth Walker; Thomas R Ziegler; Rabin Tirouvanziam; Susu M Zughaier; Supavit Chesdachai; Wendy A Hermes; James F Chmiel; Ruth E Grossmann; Amit Gaggar; Patricia M Joseph; Jessica A Alvarez
Journal:  Am J Clin Nutr       Date:  2019-03-01       Impact factor: 7.045

Review 8.  Endocrine Disorders in Cystic Fibrosis.

Authors:  Scott M Blackman; Vin Tangpricha
Journal:  Pediatr Clin North Am       Date:  2016-08       Impact factor: 3.278

9.  Cystic fibrosis improves COVID-19 survival and provides clues for treatment of SARS-CoV-2.

Authors:  Edward H Abraham; Guido Guidotti; Eliezer Rapaport; David Bower; Jack Brown; Robert J Griffin; Andrew Donnelly; Ellen D Waitzkin; Kenon Qamar; Mark A Thompson; Sukumar Ethirajan; Kent Robinson
Journal:  Purinergic Signal       Date:  2021-05-10       Impact factor: 3.765

10.  Factors Contributing to Vitamin D Status at Hospital Admission for Pulmonary Exacerbation in Adults With Cystic Fibrosis.

Authors:  Anirudh Bhimavarapu; Qiao Deng; Marta Bean; Nick Lee; Thomas R Ziegler; Jessica Alvarez; Vin Tangpricha
Journal:  Am J Med Sci       Date:  2020-08-20       Impact factor: 2.378

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.